hATTR amyloidosis

Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial

Long-term analysis of health-related quality of life outcomes in hereditary transthyretin amyloidosis patients treated with inotersen, demonstrating sustained benefits over extended follow-up.